rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    GPCR
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Structure Therapeutics (GPCR) Posts Wider Losses, Is The Discount Too Deep?

      Structure Therapeutics (GPCR) put its third quarter in focus for investors after reporting a wider net loss of US$144.76 million and a higher loss per share, with year-to-date figures showing a similar pattern. Structure Therapeutics’ share price has fallen sharply over 2026, with a year to date share price return of down 70.64% and a 90 day share price return of down 62.64%. The 1 year total shareholder return is down 46.58%, pointing to fading momentum as investors react to widening losses...

      Nov 16Yahoo FinanceGPCR
      Structure Therapeutics stock hits 52-week low at $18.68
      Nov 16Investing.comGPCR
      Unlearn and Structure Therapeutics Collaborate to Apply AI-Generated Digital Twins in Obesity Research
      Nov 12Yahoo FinanceGPCR
      Structure Therapeutics stock hits 52-week low at $20.28
      Nov 4Investing.comGPCR
      Structure Therapeutics stock hits 52-week low at $20.67
      Oct 28Investing.comGPCR
      Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026
      Oct 19Yahoo FinanceGPCR
      Structure Therapeutics (GPCR) Stock May Be A Bargain Given Its Asset Base
      Oct 17Yahoo FinanceGPCR
      Structure Therapeutics stock hits 52-week low at $21.45
      Oct 16Investing.comGPCR
      Structure Therapeutics stock hits 52-week low at 25.56 USD
      Oct 8Investing.comGPCR
      Structure Therapeutics (GPCR) Gains Fresh Obesity Trial Backing Following Data That Keeps Valuation In Focus

      Structure Therapeutics (GPCR) has put fresh clinical data for its oral obesity pipeline in front of investors, highlighting results from early stage ACCG-2671 studies and longer term aleniglipron weight loss trials. Recent trading tells a mixed story for Structure Therapeutics. The 1-day share price return of 5.17% to US$36.81 came after a year-to-date share price decline of 45.96%. Meanwhile, the 1-year total shareholder return of 50.55% points to strong longer term momentum that has cooled...

      Sep 22Yahoo FinanceGPCR
      Structure Therapeutics at Morgan Stanley conference: oral pipeline gains ground
      Sep 16Investing.comGPCR
      Structure Therapeutics (GPCR): Will Repeat Dosing Confirm Its 3.3% Weight-Loss Signal?

      Structure Therapeutics Inc. (NASDAQ:GPCR) reported September 8 results for ACCG-2671, an oral dual amylin and calcitonin receptor agonist. The single-dose portion of a Phase 1/2a trial enrolled 31 healthy adults without obesity. Six participants receiving 10 milligrams recorded a mean 3.3% body-weight reduction at day 24. For investors, the attraction is measurable activity after one […]

      Sep 10Yahoo FinanceGPCR
      Structure Therapeutics at Cantor conference: oral obesity push advances
      Sep 10Investing.comGPCR
      Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Belite Bio, Inc. ADR (BLTE) and BridgeBio Oncology Therapeutics (BBOT)

      Tipranks Press Release.

      Sep 10The Globe and MailBLTEGPCR
      Canaccord Genuity Remains a Buy on Structure Therapeutics, Inc. Sponsored ADR (GPCR)

      Detailed price information for Structure Therapeutics Inc (GPCR-Q) from The Globe and Mail including charting and trades.

      Sep 10The Globe and MailGPCR
      Structure Therapeutics Inc. (GPCR) Discusses Positive Clinical Data Updates for Oral Small Molecule Amylin and GLP-1 Programs in Chronic Weight Management - Slideshow (NASDAQ:GPCR) 2026-09-09
      Sep 9Seeking AlphaGPCR
      Structure Therapeutics: The Amylin Data Changes The Math (NASDAQ:GPCR)
      Sep 9Seeking AlphaGPCR
      Analysts Are Bullish on These Healthcare Stocks: enGene Holdings (ENGN), Structure Therapeutics, Inc. Sponsored ADR (GPCR)

      Detailed price information for Engene Therapeutics Inc (ENGN-Q) from The Globe and Mail including charting and trades.

      Sep 9The Globe and MailENGNGPCR
      Structure Therapeutics stock price target maintained at $70 by H.C. Wainwright
      Sep 9Investing.comGPCR
      Citizens reiterates Structure Therapeutics stock rating on trial data
      Sep 9Investing.comGPCR
      Structure Therapeutics Advances Weight-Loss Pills With New Clinical Data
      Sep 8BenzingaGPCR
      Structure Therapeutics falls after trial data for lead obesity drugs
      Sep 8Seeking AlphaGPCR
      Jefferies raises Structure Therapeutics stock target on amylin data
      Sep 8Investing.comGPCRJEF
      Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management

      ACCG-2671 (oral small molecule amylin receptor agonist) demonstrated a ~6-day half-life, no serious adverse events, and evidence of target engagement including up to 3.3% body weight loss in Phase 1/2a SAD clinical trial First participants dosed with ACCG-2671 in the 12-week MAD portion of the Phase 1/2a clinical trial; topline data expected in 1H 2027 Aleniglipron (oral small molecule selective GLP-1 receptor agonist) demonstrated up to 16.2% mean reduction in body weight at 72 weeks with no ob

      Sep 8Yahoo FinanceGPCR
      Structure Therapeutics Reports Up to 16.2% Weight Loss in Aleniglipron Trial
      Sep 8Yahoo FinanceGPCR
      Structure’s Obesity Pill Cuts Body Weight by 16% in Study
      Sep 8BloombergGPCR
      Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences

      SAN FRANCISCO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that management will participate in three upcoming healthcare conferences in September: 2026 Cantor Global Healthcare ConferenceDate: Thursday, September 10Format: Fireside chat and 1x1 meetingsTime: 3:55 – 4:25 PM EDTLocation: New York, NY

      Sep 3Yahoo FinanceGPCR
      Structure Therapeutics - A Strong Bet For An Oral GLP-1 Approval Before 2030 (NASDAQ:GPCR)
      Aug 21Seeking AlphaGPCR

      This is the newest page. Registered accounts read further back.